Benefits
Antioxidant blood markers in a 19-person athlete trial
In the one positive human trial, 19 rowers from the Polish national team took 500 mg a day for 6 weeks (10 on GliSODin, 9 on placebo). The supplemented group ended with higher SOD activity in their red blood cells and lower C-reactive protein, a marker of inflammation. Those are blood measurements in a very small group of elite athletes, not a health outcome for an everyday user. A second trial in 38 women aged 50 to 65 with self-reported fatigue found no significant difference from placebo after 12 weeks, and the placebo group actually improved slightly more (fatigue fell 1.6% on GliSODin versus 4.1% on placebo).
Airway effects seen only in mice
The airway research behind this claim was done in mice with experimentally induced asthma, not in people. No human study has tested whether GliSODin affects immune function or breathing, and results in mice frequently do not carry over to humans.
Skin: not shown for the supplement on its own
Nothing cited here measured skin. The one published human skin study of a GliSODin formula also had participants use prescription tazarotene 0.1% cream, so any skin change in that study cannot be credited to the oral supplement.
Mechanism of action
SOD induction
The proposed idea is that the gliadin-protected SOD prompts the body to make more of its own antioxidant enzymes rather than acting as a direct antioxidant itself. The only human support for this is the rise in red blood cell SOD activity measured in 19 rowers over 6 weeks.
Anti-inflammatory signaling
In mice with induced asthma, the melon SOD complex reduced airway inflammation and shifted T-cell activity. This chain of events has not been tested in people.
Clinical trials
Laboratory study in a mouse model of asthma, looking at airway inflammation and T-cell differentiation. (Klein et al. 2023, Frontiers in Allergy)
Mice with experimentally induced asthma. No people took part.
In these mice, GliSODin prevented airway inflammation and altered T-cell differentiation. Findings in mice often do not repeat in humans, and no human trial has tested GliSODin for airway or immune outcomes. Asthma is a medical condition that needs a doctor's care; this is not a treatment for it.